Epidemiology and Factors Associated with Treatment Success of Invasive Fungal Infections Among Newly Hematologic Malignancy Patients Receiving Chemotherapy or Hematopoietic Stem Cell Transplant in Thailand

References

• Bays DJ, Thompson GR 3rd. Fungal Infections of the stem cell transplant recipient and hematologic malignancy patients. Infect Dis Clin North Am. 2019;33(2):545–566.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068–1075.
   PubMed Web of Science ®Google Scholar
• Rotjanapan P, Chen YC, Chakrabarti A, et al. Epidemiology and clinical characteristics of invasive mould infections: a multicenter, retrospective analysis in five Asian countries. Med Mycol. 2018;56(2):186–196.
   PubMedGoogle Scholar
• Pagano L, Dragonetti G, Cattaneo C, et al. Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report. Haematologica. 2017;102(10):e407–e410.
   PubMedGoogle Scholar
• Phikulsod P, Suwannawiboon B, Chayakulkeeree M. Invasive Fungal Infection among Febrile Patients with Chemotherapy-Induced Neutropenia in Thailand. Se Asian J Trop Med. 2017;48(1):159–169.
   PubMed Web of Science ®Google Scholar
• Nganthavee V, Phutthasakda W, Atipas K, et al. High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes. Support Care Cancer. 2019;27(9):3613–3622.
   PubMed Web of Science ®Google Scholar
• Supatharawanich S, Narkbunnam N, Vathana N, et al. Invasive Fungal Diseases in Children with Acute Leukemia and Severe Aplastic Anemia. Mediterr J Hematol Infect Dis. 2021;13(1):e2021039.
   PubMedGoogle Scholar
• CLSI. Performance Standards for Antifungal Susceptibility Testing of Yeasts (M60). 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
   Google Scholar
• CLSI. Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi (M61). 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
   Google Scholar
• Donnelly JP, Chen SC, Kauffman CA, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367–1376.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–1821.
   PubMed Web of Science ®Google Scholar
• Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47(5):674–683.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Hoenigl M, Lass-Florl C, et al. Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses. 2019;62(9):716–729.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Girmenia C, Bruggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221–3230.
   PubMed Web of Science ®Google Scholar
• Auberger J, Lass-Florl C, Ulmer H, et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2008;88(5):508–515.
   PubMed Web of Science ®Google Scholar
• Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265–273.
   PubMed Web of Science ®Google Scholar
• Fracchiolla NS, Sciume M, Orofino N, et al. Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: results from a single-centre study. PLoS One. 2019;14(5):e0216715.
   PubMedGoogle Scholar
• Karthaus M, Cornely OA. Recent developments in the management of invasive fungal infections in patients with hematological malignancies. Ann Hematol. 2005;84(4):207–216.
   PubMedGoogle Scholar
• Caira M, Girmenia C, Fadda RM, et al. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur J Haematol. 2008;81(3):242–243.
   PubMed Web of Science ®Google Scholar
• Camplesi MJ, Silva HM, Arantes AM, et al. Invasive fungal infection in patients with hematologic disorders in a Brazilian tertiary care hospital. Rev Soc Bras Med Trop. 2017;50(1):80–85.
   PubMedGoogle Scholar
• Bergamasco MD, Pereira CAP, Arrais-Rodrigues C, et al. Epidemiology of Invasive Fungal Diseases in Patients with Hematologic Malignancies and Hematopoietic Cell Transplantation Recipients Managed with an Antifungal Diagnostic Driven Approach. J Fungi. 2021;7(8);56.
   Google Scholar
• Kurosawa M, Yonezumi M, Hashino S, et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2012;96(6):748–757.
   PubMed Web of Science ®Google Scholar
• Lee SY, Yeo CL, Lee WH, Kwa AL, Koh LP, Hsu LY. Prevalence of invasive fungal disease in hematological patients at a tertiary university hospital in Singapore. BMC Res Notes. 2011;4:42.
   PubMedGoogle Scholar
• Chen CY, Huang SY, Tsay W, et al. Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001-2010. Int J Antimicrob Agents. 2012;40(6):533–538.
   PubMed Web of Science ®Google Scholar
• Roongpoovapatr P. Causative Pathogens of Fever in Neutropenic Patients at King Chulalongkorn Memorial Hospital. J Med Assoc Thai. 2010;93(7):776–783.
   PubMedGoogle Scholar
• Ruhnke M, Schwartz S. Recent developments in the management of invasive fungal infections in patients with oncohematological diseases. Ther Adv Hematol. 2016;7(6):345–359.
   PubMed Web of Science ®Google Scholar
• Oh SM, Byun JM, Chang E, et al. Incidence of invasive fungal infection in acute lymphoblastic and acute myelogenous leukemia in the era of antimold prophylaxis. Sci Rep. 2021;11(1):22160.
   PubMedGoogle Scholar
• Wasylyshyn A, Linder KA, Castillo CG, Zhou S, Kauffman CA, Miceli MH. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia. Mycopathologia. 2020;185(2):299–306.
   PubMed Web of Science ®Google Scholar
• Patel HP, Perissinotti AJ, Patel TS, Bixby DL, Marshall VD, Marini BL. Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy. Open Forum Infect Dis. 2019;6(5):ofz176.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–1100.
   PubMed Web of Science ®Google Scholar
• Souza L, Nouer SA, Morales H, et al. Epidemiology of invasive fungal disease in haematologic patients. Mycoses. 2021;64(3):252–256.
   PubMedGoogle Scholar
• Perea S, Patterson TF. Invasive Aspergillus infections in hematologic malignancy patients. Semin Respir Infect. 2002;17(2):99–105.
   PubMedGoogle Scholar
• Chen CY, Sheng WH, Cheng A, et al. Invasive fungal sinusitis in patients with hematological malignancy: 15 years experience in a single university hospital in Taiwan. BMC Infect Dis. 2011;11:250.
   PubMedGoogle Scholar
• Zarrinfar H, Mirhendi H, Fata A, Khodadadi H, Kordbacheh P. Detection of Aspergillus flavus and A. fumigatus in Bronchoalveolar Lavage Specimens of Hematopoietic Stem Cell Transplants and Hematological Malignancies Patients by Real-Time Polymerase Chain Reaction, Nested PCR and Mycological Assays. Jundishapur J Microbiol. 2015;8(1):e13744.
   PubMed Web of Science ®Google Scholar
• Acet-Ozturk NA, Omer-Topcu D, Vurat-Acar K, et al. Impact of revised EORTC/MSGERC 2020 criteria on diagnosis and prognosis of invasive pulmonary aspergillosis in patients with hematological malignancies undergoing bronchoscopy. J Mycol Med. 2022;32(4):101304.
   PubMedGoogle Scholar
• Dewan E, Biswas D, Kakati B, Verma SK, Kotwal A, Oberoi A. Epidemiological and mycological characteristics of candidemia in patients with hematological malignancies attending a tertiary-care center in India. Hematol Oncol Stem Cell Ther. 2015;8(3):99–105.
   PubMedGoogle Scholar
• Barreto JN, Thompson CA, Mara KC, et al. Incidence and Outcomes of Pneumocystis pneumonia When Utilizing PCR-Based Diagnosis in Patients with Hodgkin Lymphoma Receiving Intensive Chemotherapy. Blood. 2019;134(Supplement_1):4052.
   Google Scholar
• Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350–1360.
   PubMed Web of Science ®Google Scholar
• Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica. 2006;91(7):986–989.
   PubMed Web of Science ®Google Scholar
• Chayakulkeeree M, Denning DW. Serious fungal infections in Thailand. Eur J Clin Microbiol Infect Dis. 2017;36(6):931–935.
   PubMedGoogle Scholar
• Hsu LY, Lee DG, Yeh SP, et al. Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study. Clin Microbiol Infect. 2015;21(6):594 e597–511.
   Google Scholar
• Lerolle N, Raffoux E, Socie G, et al. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. Clin Microbiol Infect. 2014;20(11):O952–959.
   PubMed Web of Science ®Google Scholar
• Biehl LM, Vehreschild JJ, Liss B, et al. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis. J Antimicrob Chemother. 2016;71(9):2634–2641.
   PubMedGoogle Scholar
• Kuster S, Stampf S, Gerber B, et al. Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: a Swiss transplant cohort study. Transpl Infect Dis. 2018;20(6):e12981.
   PubMedGoogle Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–359.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–347.
   PubMed Web of Science ®Google Scholar